



Empowering people worldwide to live healthier at every stage of life

VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver quality medicines to patients when and where they need them.

OUR MISSION

At Viatris, we see healthcare not as it is, but as it should be. We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs.

Viatris empowers people worldwide to live healthier at every stage of life.

We do so *via*:

ACCESS

providing high quality, trusted medicines to patients regardless of geography or circumstance

LEADERSHIP

advancing sustainable operations and innovative solutions to improve patient health

PARTNERSHIP

leveraging our collective expertise to connect people to products and services

OUR LEADERS

Our seasoned executive management team and board of directors bring decades of expertise, knowledge and strategic vision to Viatris. Together with our dedicated and talented global workforce, our leadership is committed to increasing access to medicine for patients around the world while unlocking value for shareholders.



Robert J. Coury
Executive Chairman



Michael Goettler
Chief Executive Officer



Rajiv Malik
President



Sanjeev Narula
Chief Financial Officer

FAST FACTS¹

NASDAQ Ticker: VTRS

Offices:

Headquartered in the U.S. with global centers in Pittsburgh, Hyderabad and Shanghai

Global Workforce: ~45,000

Including expertise across scientific, manufacturing, regulatory, commercial and medical

Manufacturing Facilities: ~50

Across oral solid doses, injectables, complex dosage forms and API

Annual Production Capacity:

80+ billion doses

Molecules: 1,400+

- Portfolio that treats nine out of 10 WHO leading causes of death
- 200+ medicines on WHO Essential Medicines List

Commercial Reach:

165+ countries and territories

Customers: 60,000+

Including retail and pharmacy establishments, wholesalers, governments, institutions and physicians

OUR PRODUCTS

Our global portfolio includes medicines across a broad range of major therapeutic areas, spanning both noncommunicable and infectious diseases.

Brands

Best-in-class, iconic brand-name products and global key brands

Generics

A diverse range of generic medicines, including branded and complex generics

Biosimilars

One of the industry's largest and most diverse global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology

Over-the-counter (OTC)

Variety of OTCs, including dietary supplements, homeopathics and cosmetics

Active Pharmaceutical Ingredients (API)

One of the world's largest producers of APIs


¹Data as of November 2020.
©2020 Viatris Inc. All Rights Reserved. VIATRIS, the VIATRIS Logo, GLOBAL HEALTHCARE GATEWAY and PARTNER OF CHOICE are trademarks of Mylan Inc., a Viatris Company.

Creating better value

for all stakeholders while addressing unmet needs.



Committed to Corporate Social Responsibility



PATIENT HEALTH

An industry leader with products that are capable of addressing nine of the top 10 causes of death globally and serving more than 165 countries and territories including close to 90% of low and lower-middle-income countries²



EMPLOYEE HEALTH

Committed to providing a safe, positive, and productive work environment that fosters inclusion, integrity, dignity and mutual respect



COMMUNITY HEALTH

Support efforts to enhance the quality of life and meet needs in and around the communities where Viatris operates



ENVIRONMENTAL HEALTH

Responsible environmental stewardship and promoting safe and sustainable operations is a priority



GLOBAL PUBLIC HEALTH

Leverage our global footprint to advocate for responsible public policy, prioritizing patient health, access to medicine, including in low-income countries, and the acceptance of generics and biosimilars

STAY CONNECTED

Media Relations
+1.724.514.1968
Communications@viatris.com

Investor Relations
+1.724.514.1813
InvestorRelations@viatris.com



Viatris.com



Follow Viatris on LinkedIn



Follow us @viatrisinc



Subscribe to our YouTube channel

²According to the World Health Organization. For additional information, please visit: <https://extranet.who.int/prequal/>